AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03326999 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Saline as placebo comparator
Study NCT01745861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lipidem (Omega-3 fish oil lipid emulsion)
Description: Lipidem 200 mg/ml daily infusion for 7 days maximum
Study NCT01745861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lipofundin® MCT/LCT 20%
Description: Lipofundin® MCT/LCT 20% daily infusion for 7 days
Study NCT04393545 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hallux valgus night splint
Description: The HV night splint holds the hallux in abduction in order to provide a correct position. The SP group was given splints consisting of a rigid polyethylene bar along the medial of the hallux, and soft polyform and Velcro fastener parts.
Study NCT04393545 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: The exercises involved strengthening the AbdH (abductor hallucis) and plantar fascia muscles, and stretching the hallux
Study NCT04393545 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy
Description: Two self-adhesive electrodes were used. One was placed over the medial distal end of the first metatarsal and the other was attached to the motor point of the AbdH (inferior and posterior to the navicular tuberosity).21 The stimulation intensity was increased until a contraction was observed without causing discomfort and pain. Twenty-minute HVPGS was applied in total over three weekly sessions for four weeks.
Study NCT03043183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perioperational nutrition surpport
Description: Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
Study NCT02216331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description.
Study NCT04150250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iOWH032
Description: Anti-secretory synthetically manufactured small molecule designed to inhibit the cystic fibrosis transmembrane conductance regulator chloride channel.
Study NCT04150250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets matching iOWH032 on taste, appearance, dissolution time with the same excipients but no active ingredients.
Study NCT04150250 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: V. cholerae Challenge
Description: Freshly-harvested, wild-type Vibrio (V.) cholerae El Tor Inaba strain N16961,10\^6 cfu suspended in 30 mL of sodium bicarbonate solution ingested orally.
Study NCT04150250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V. cholerae Challenge
Description: Freshly-harvested, wild-type Vibrio (V.) cholerae El Tor Inaba strain N16961,10\^6 cfu suspended in 30 mL of sodium bicarbonate solution ingested orally.
Study NCT04150250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotics
Description: Antibiotic therapy may include:~* Ciprofloxacin 500 mg, twice daily;~* Azithromycin 500 mg, once daily (for those persons who are allergic to fluoroquinolones);~* Doxycycline 300 mg, once daily (for those persons who are allergic to fluoroquinolones)
Study NCT04150250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Antibiotic therapy may include:~* Ciprofloxacin 500 mg, twice daily;~* Azithromycin 500 mg, once daily (for those persons who are allergic to fluoroquinolones);~* Doxycycline 300 mg, once daily (for those persons who are allergic to fluoroquinolones)
Study NCT02579941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling (pregnant)
Description: 5.4 ml of venous blood will be taken during the delivery or the caesarian procedure, in addition to the standard of care blood sampling.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM.
Study NCT03889457 — intervention group
Intervention type: OTHER
Intervention: anticoagulation choice
Description: Type of anticoagulant chosen by the patient (oral or injectable).
Study NCT04412876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine 30 mg qd
Study NCT02327871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal cooling device (and usual standard procedure)
Description: Standard treatments for resuscitation after CA will follow local, national, and international guidelines. Core temperature is measured using urinary Foley catheters and/or arterial temperature monitoring if available. During TH, sedation and analgesia is performed in routine. Neuromuscular blockade is induced to favor cooling and prevent shivering if necessary. Circulatory function is monitored by arterial catheter if necessary and blood pressure is maintained as usually. Hypotension is treated with dobutamine catecholamines titrated according cardiac output monitored using echocardiogram, or PiCCO® systems. Fluid management is left at the discretion of the attending physician. Prognostication after CA uses serial clinical examinations, biomarkers, transcranial Doppler, Electro-Encephalo-Gram, cerebral CT-scan or MRI, and/or Somato-Sensory-Evoked-Potential.
Study NCT04473222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Well!
Description: Sleep Well! is a brief, behavioral sleep intervention. The intervention was originally comprised of healthy sleep advice and tested in the context of a sleep health education campaign for impoverished children. Based on preliminary research regarding the need for sleep intervention in primary care, Investigators have expanded the intervention to more comprehensively address poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers who are living in disadvantaged contexts. Intervention components are based on effective pediatric behavioral sleep treatments.
Study NCT04473222 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep education
Description: Sleep education for caregivers of toddlers and preschoolers is provided via a Parent Family Education handout available to families and clinicians in the CHOP primary care network. The handout contains evidence-based advice about healthy sleep in early childhood.
Study NCT01210560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan MR
Description: 20 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
Study NCT01210560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan MR
Description: 20 mg Tolvaptan MR capsule(morning and afternoon); Placebo capsules/tablets (morning and afternoon) for 7 days
Study NCT01210560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan MR
Description: 60 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
Study NCT01210560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan IR
Description: 90 mg Tolvaptan IR tablet(morning); 30 mg Tolvaptan IR tablet (afternoon); Placebo capsules (morning and afternoon) for 7 days
Study NCT01210560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan MR
Description: 120 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
Study NCT01769573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RG-HRV16
Description: A suspension of the RG-HRV16 virus in Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin
Study NCT04412876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Description: Imipramine 25mg qd
Study NCT01769573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo to be used will be Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin. Placebo will be supplied in 2 ml borosilicate glass vials sealed with butyl stoppers containing 0.5 ml.
Study NCT03250065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of prototype sensor to a standard endotracheal tube
Description: During anaesthesia the device under study, a prototype saturation sensor will be applied to a standard endotracheal tube that ventilates the patient as normal.
Study NCT03256708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prolardii
Description: Prolardii: 2 capsules per day for 12 to 15 days
Study NCT03256708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredients
Study NCT03160365 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ACQUISITION OF IMAGES
Description: In addition to the conventional clinical protocol, 4 MRIs qere performed at Day 0, day 1,day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
Study NCT03904251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV
Study NCT03904251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study NCT03943043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Phase I dosing regimens:~The dose of treatment will be assigned at the time of enrolment in one of these 3 subsequent dose-levels:~- 1° level: gemcitabine 800 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 80 mg/m2 0° level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 100 mg/m2~1. level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 125 mg/m2~2. level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 150 mg/m2 each administered on day 1, every 14 day~Phase II:~Gemcitabine plus oxaliplatin plus nab-paclitaxel according to RP2D.
Study NCT03404037 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum endostatin level
Description: An oral (metoprolol 20 mg) was given to the patients with heart rates > 60 beats/minute and had no contraindications to beta-blockers, one hour before the scan. Sublingual nitroglycerin was given to all patients before CT examination. A 64-slice CT scanner (Sensation 64; Siemens Medical System, Germany) was used for imaging all subjects. All CT examinations were done during inspiratory breath holding.~Endostatin levels were measured using a sandwich ELISA kit according to the manufacturer's instructions endostatin ELISA kit (R\&D Systems, Minneapolis, Minnesota, USA
Study NCT02680704 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PEEP titrated mechanical ventilation
Description: Enrolled patients will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O. Intracranial pressure, transpulmonary pressure, vitals, and mechanical ventilator data will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set > 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period.
Study NCT01683435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBA binding assay
Description: HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
Study NCT03762265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rilzabrutinib
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT03762265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT03762265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT04231825 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial alternating current stimulation
Description: Transcranial alternating current stimulation across the prefrontal cortex using electrodes F3 and F4.
Study NCT04231825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation
Description: Transcranial alternating current stimulation across the prefrontal cortex using electrodes F3 and F4.
Study NCT02279654 — intervention group
Intervention type: DRUG
Intervention: Lenalidomide
Description: Lenalidomide as prescribed in routine clinical practice for low to intermediate-1 risk MDS
Study NCT02356588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil Tablet 30 mcg
Study NCT02914496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: ACT is a specific form of Cognitive behavior therapy (CBT) which will be given as a course consisting of seven sessions where each session is two hours long.
Study NCT02523079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy for Insomnia
Study NCT02523079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Self-help Therapy for Insomnia
Study NCT02523079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Guidance
Study NCT02356588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Study NCT02216331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine
Study NCT02216331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Study NCT04231617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glibenclamide
Description: Oral administration of glibenclamide or placebo. To investigate the role of CGRP on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
Study NCT04231617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CGRP infusion
Description: CGRP infusion
Study NCT04231617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00253435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim 5 micrograms/kg/day S.C. or IV will be given daily beginning on Day 0. The first dose should begin four hours after the stem cell infusion is completed. Filgrastim will continue daily until the ANC >=1500/uL for three consecutive days.
Study NCT00253435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The carboplatin will be administered as a continuous IV infusion Day - 7 through Day - 4, with dosing based upon pretreatment GFR levels. The carboplatin should be diluted to a concentration of 0.3 mg/ml in D5W 0.45NS and infused concomitantly with etoposide through the same central venous catheter using a Y connector; a controlled rate infusion pump is used for each arm of the Y.
Study NCT00253435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: The etoposide shall be administered day -7 through day -4 via continuous intravenous infusion over 96 hours. For patients with a corrected GFR >= 100 ml/min/1.72 m\^2, a dose of 300 mg/m\^2/day (10 mg/kg/day if child is \< 12 kg) shall be given. For patients with a corrected GFR 60-99 ml/min/1.72 m\^2, the etoposide will be administered at a dose of 160 mg/m\^2/day (5.3 mg/kg/day). The etoposide will be diluted in D5W 0.45%NS at a concentration of \< 0.4 mg/ml. Etoposide should not be mixed with carboplatin, but administered using a Y-connector.
Study NCT00253435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: For patients in either the normal GFR strata (>=100 ml/min/1.73 m\^2), or reduced GFR strata (60-99 ml/min/1.73m\^2), melphalan shall be administered at a dose of 60 mg/m\^2/day (2 mg/kg/day if child is \< 12 kg) on day -7, -6, and -5 of study. The melphalan should be infused at a rate of less than 10 mg/minute, and should complete within 1 hour of reconstitution each day. The melphalan should be diluted in 0.9% NaCl at a concentration \< 2 mg/ml. The total dosage of melphalan to be administered will be 180 mg/m\^2.
Study NCT00253435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell infusion
Description: Stem cells or marrow will be infused on day 0 of study therapy. Where the DMSO concentration in the stem cell product would exceed accepted level for infusion within a 24 hour period, stem cell products may be infused over two days to meet this standard. For purged PBSC: A minimum of 2.0 x 10\^6 viable CD34+ cells/kg must be available. For unpurged PBSC, a minimum of 2.0 x 10\^6 viable CD34+ cells/kg must be available. Having a back-up of 2.0 x 10\^6 viable CD34+ cells/kg purged or unpurged PBSC is recommended but not required. For purged bone marrow, a minimum of 1.5 x10\^8 mononuclear cells/kg must be available.
Study NCT01592227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed paracetamol
Description: Marketed paracetamol
Study NCT01592227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental paracetamol formulation
Description: Experimental paracetamol formulation
Study NCT00253435 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I-MIBG
Description: Therapeutic 131I MIBG will be synthesized by Draximage Canada.with specific activity between 15 and 25mCi/ml. Radiopurity will be initially determined by Draximage, prior to shipment to participating centers. Free radioiodide content must then be rechecked at the treating center prior to infusion using HPLC or Sep-Pac methodology.
Study NCT03851731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Intranasal spray
Study NCT03851731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Intranasal spray
Study NCT03851731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexol
Description: Intranasal spray
Study NCT03983746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: core stability exercises and treadmill training exercises
Description: Forty-five children with Down syndrome included in the study. The children aged 4-6 years, and they were equally divided randomly into three groups (A), (B) and (C). Group A received traditional physical therapy intervention strategies to facilitate the balance of participated children. Group (B) received same as the group (A), with additional core stability exercises training. Group (C) received same intervention strategies as group (A) in conjunction with a treadmill exercise program. The children's balance was evaluated using the Berg Balance Scale and the Biodex Balance System. Treatment sessions were for 60 min, thrice a week, for eight consecutive weeks.
Study NCT00253435 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Local irradiation is to be given to previously non-irradiated primary and metastatic sites of disease. Local irradiation should not start till the patient is medically stable, has an ANC > 1000/uL, platelets > 30,000 / uL, and is > 42 days post transplant. Recommended radiation guidelines consist of 2160 cGy total, given over 12 days using a single 180 cGy fraction/day. Any delay in local radiation that would extend treatment beyond day +84 should be discussed with the study chair. Local radiation will be administered at a participating NANT member site.
Study NCT00490750 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dor fundoplication
Description: Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Dor fundoplication
Study NCT00490750 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toupet fundoplication
Description: Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Toupet fundoplication
Study NCT01496677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA 200 mg
Description: Single oral tablet of TR-701 FA to elderly subjects
Study NCT01496677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA 200 mg
Description: Single oral tablet of TR-701 FA to younger group (18-45 years old)
Study NCT03711942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra orifice barrier
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.3mm GP in the orifice was removed and intraorifice barrier and 2mm thick base was given of GIC.
Study NCT03711942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Base
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.2mm thick Base of GIC was applied over the orifice before composite restoration